Table 2.
Changes in scores of the applied scales due to discontinuation of trimetazidine.
| Baseline [mean ± SD or n (%)] | Follow-upa [mean ± SD or n (%)] | Change | p-value | |||
|---|---|---|---|---|---|---|
| Absolute (mean ± SD) | Relative change (%)b (mean) | |||||
| MDS-UPDRS Part I | 15.0 ± 7.1 | 10.9 ± 6.6 | −4.0 ± 4.4 | −25.7 | <0.001 | |
| MDS-UPDRS Part II | 13.1 ± 8.4 | 9.6 ± 6.9 | −3.5 ± 4.7 | −23.8 | <0.001 | |
| MDS-UPDRS Part III | 38.2 ± 14.4 | 27.8 ± 13.5 | −10.4 ± 6.7 | −28.5 | <0.001 | |
| MDS-UPDRS Part IV | 3.4 ± 3.2 | 2.2 ± 2.4 | −1.2 ± 2.6 | −30.1 | 0.004c | |
| PIGD score | 10.6 ± 6.2 | 7.5 ± 5.2 | −3.1 ± 3.2 | −27.9 | <0.001 | |
| HYS | 0 | 0 (0.0) | 2 (4.8) | 0.008d | ||
| 1 | 1 (2.4) | 3 (7.1) | ||||
| 2 | 24 (57.1) | 28 (66.7) | ||||
| 3 | 9 (21.4) | 4 (9.5) | ||||
| 4 | 7 (16.7) | 5 (11.9) | ||||
| 5 | 1 (2.4) | 0 (0.0) | ||||
| Change in HYS after TMZ discontinuation | Improvement | 16 (38.1) | ||||
| No change | 23 (54.8) | |||||
| Worsening | 3 (7.1) | |||||
| NMSS | ||||||
| Cardiovascular problems | 3.5 ± 3.7 | 2.4 ± 3.2 | −1.1 ± 3.7 | −28.6 | 0.053c | |
| Sleep problems | 14.3 ± 8.9 | 10.1 ± 7.3 | −4.1 ± 7.3 | −24.7 | 0.001 | |
| Mood problems | 14.7 ± 17.0 | 11.4 ± 13.4 | −3.3 ± 13.5 | −19.7 | 0.119 | |
| Hallucinations | 1.7 ± 3.9 | 1.8 ± 5.3 | 0.1 ± 5.3 | 5.1 | 0.931 | |
| Memory problems | 6.7 ± 7.7 | 4.8 ± 5.9 | −1.9 ± 6.9 | −23.6 | 0.085 | |
| Gastrointestinal problems | 5.5 ± 8.0 | 3.1 ± 5.2 | −2.4 ± 6.7 | −39.1 | 0.024 | |
| Urinary problems | 12.2 ± 10.0 | 9.6 ± 8.7 | −2.5 ± 8.5 | −20.5 | 0.060 | |
| Sexual problems | 0.9 ± 3.9 | 0.2 ± 0.5 | −0.7 ± 3.9 | −76.0 | 0.261c | |
| Miscellaneous | 3.4 ± 5.0 | 3.3 ± 4.6 | −0.2 ± 4.0 | −5.8 | 0.790c | |
| Total | 62.8 ± 49.9 | 46.6 ± 35.3 | −16.2 ± 34.6 | −25.6 | 0.004 | |
| MADRS | 14.3 ± 8.8 | 11.4 ± 6.4 | −3.0 ± 5.4 | −20.1 | 0.001 | |
| PDSS-2 | 17.5 ± 10.9 | 15.1 ± 11.4 | −2.4 ± 8.3 | −13.8 | 0.068 | |
| ESS | 6.4 ± 4.7 | 5.5 ± 4.7 | −0.9 ± 5.0 | −9.3 | 0.246 | |
| MoCA | 22.2 ± 4.0 | 22.9 ± 4.0 | 0.5 ± 2.8 | 1.7 | 0.374 | |
| PDQ-39 | ||||||
| Mobility | 30.2 ± 29.5 | 24.3 ± 23.6 | −6.2 ± 18.9 | −20.7 | 0.043 | |
| Activities of daily living | 20.7 ± 23.7 | 15.2 ± 16.4 | −5.7 ± 19.3 | −27.2 | 0.067 | |
| Stigma | 18.3 ± 27.3 | 13.1 ± 24.0 | −5.6 ± 16.5 | −26.2 | 0.034 | |
| Emotional well-being | 25.5 ± 18.5 | 25.3 ± 18.0 | −0.2 ± 13.0 | −0.4 | 0.920 | |
| Social support | 11.1 ± 14.0 | 6.9 ± 10.0 | −4.5 ± 13.9 | −37.2 | 0.046 | |
| Cognition | 19.6 ± 16.3 | 19.1 ± 13.4 | −0.8 ± 12.1 | −3.7 | 0.692 | |
| Communication | 14.7 ± 22.5 | 12.6 ± 21.3 | −2.4 ± 17.9 | −15.1 | 0.388 | |
| Bodily discomfort | 36.3 ± 24.1 | 31.1 ± 23.0 | −5.3 ± 22.1 | −11.1 | 0.134 | |
| Summary index | 21.9 ± 16.5 | 18.3 ± 13.9 | −3.8 ± 10.8 | −18.2 | 0.031 | |
aFollow-up examinations were performed 95 ± 25 days after the baseline visit.
bTo calculate relative change the following formula was used: (ScoreBaseline-ScoreFollow-up)/ScoreBaseline*100.
cThe Wilcoxon signed rank test was used for the analysis of changes in these scores.
dThe Chi-square test was utilized for the calculation of this value.
Abbreviations: ESS = Epworth Sleepiness Scale; EQ = EuroQoL instrument; HYS = Hoehn-Yahr Scale; MADRS = Montgomery-Asberg Depression Rating Scale; MDS-UPDRS = Movement Disorder Society-sponsored Unified Parkinson’s Disease Rating Scale; MoCA = Montreal Cognitive Assessment; NMSS = Non-Motor Symptoms Scale; PDSS-2 = Parkinson’s Disease Sleep Scale 2nd version; PDQ-39 = 39-item Parkinson’s Disease Questionnaire; PIGD = postural instability and gait difficulty; TMZ = trimetazidine; VAS = visual analogue scale.